Allogeneic Carrier-specific Enhancement of Hapten-specific Secondary B-cell Responses
Overview
General Medicine
Authors
Affiliations
We have analyzed the capacity of carrier-specific T cells to enhance the immune response of hapten-specific secondary B cells which do not share genes in the H-2 complex with the T cells. For this analysis we have used the in vitro splenic focus technique which allows assessment of monoclonal responses of B cells isolated in splenic fragment cultures of irradiated reconstituted carrier primed mice. A previous report from this laboratory demonstrated that syngeny in the I region of the H-2 complex was necessary between collaborating hapten-specific primary (nonimmune) B cells and carrier-specific T cells for responses yielding IgG1 but not IgM antibody. These findings lead up to postulate that the expression of I-region gene products on the surface of primary B cells and I-region syngeny with collaborating carrier-specific T cells were essential elements in the triggering events leading to IgG1 synthesis by primary B cells. The results presented in the present report indicate that, unlike primary B cells, the majority of secondary B cells can be stimulated to produce IgG1 antibody in carrier-primed allogeneic recipients. Although the enhancement of secondary IgG1 responses is slightly greater with syngeneic T cells, the allogeneic collaborative interaction requires both carrier priming of recipient mice and stimulation with the homologous hapten-carrier complex and thus appears to be specific. These findings clearly discriminate secondary from primary B cells and indicate that the mechanism of stimulation of secondary B cells to yield IgG1-producing clones differs fundamentally from the stimulation of primary B cells in that the requisite for I-region syngeny is obviated.
16 Methods for Detecting Microbial Pathogens in Food and Water.
Kaspar C, Tartera C Methods Microbiol. 2024; 22:497-531.
PMID: 38620159 PMC: 7148849. DOI: 10.1016/S0580-9517(08)70253-8.
A mimotope peptide-based vaccine against Schistosoma mansoni: synthesis and characterization.
Arnon R, Tarrab-Hazdai R, Steward M Immunology. 2000; 101(4):555-62.
PMID: 11122460 PMC: 2327114. DOI: 10.1046/j.1365-2567.2000.00139.x.
Acetylcholinesterase from Schistosoma mansoni: interaction of globular species with heparin.
Tarrab-Hazdai R, Toker L, Silman I, Arnon R Biochem J. 1999; 344 Pt 3:945-51.
PMID: 10585885 PMC: 1220720.
Synthesis and characterization of a protective peptide-based vaccine against Schistosoma mansoni.
Tarrab-Hazdai R, Schechtman D, Arnon R Infect Immun. 1998; 66(9):4526-30.
PMID: 9712813 PMC: 108551. DOI: 10.1128/IAI.66.9.4526-4530.1998.
Bialasiewicz A, Lubach D, MARGHESCU S Arch Dermatol Res. 1981; 271(1):29-40.
PMID: 7294881 DOI: 10.1007/BF00417385.